Charles River Laboratories International Director George Massaro Unloads 5,958 Shares (CRL)
Charles River Laboratories International (NYSE:CRL) Director George Massaro sold 5,958 shares of Charles River Laboratories International stock on the open market in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $47.38, for a total transaction of $282,290.04. Following the completion of the sale, the director now directly owns 15,410 shares in the company. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on CRL. Analysts at UBS AG initiated coverage on shares of Charles River Laboratories International (NYSE:CRL) in a research note to investors on Tuesday. They set a “neutral” rating and a $49.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Robert W. Baird raised their price target on shares of Charles River Laboratories International (NYSE:CRL) from $50.00 to $52.00 in a research note to investors on Monday, August 26th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Charles River Laboratories International (NYSE:CRL) from $52.00 to $57.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock.
Three analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $46.29.
Shares of Charles River Laboratories International (NYSE:CRL) remained flat at $47.37 during trading on Tuesday. The stock had a trading volume of 294,430 shares. Charles River Laboratories International has a one year low of $35.54 and a one year high of $48.73. The stock has a 50-day moving average of $47.03 and a 200-day moving average of $44.16. The company has a market cap of $2.324 billion and a P/E ratio of 24.57.
Charles River Laboratories International (NYSE:CRL) last released its earnings data on Wednesday, July 31st. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.71 by $0.02. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $293.77 million. During the same quarter in the prior year, the company posted $0.75 earnings per share. The company’s quarterly revenue was up 3.4% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post $2.84 earnings per share for the current fiscal year.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.